Characteristic | All Patients, n = 28 | Successes, n = 20 | Failures, n = 8 | p* |
---|---|---|---|---|
Clinical | ||||
Polyarteritis nodosa, n | 9 | |||
Wegener’s granulomatosis**, n | 8 | |||
Churg-Strauss syndrome***, n | 5 | |||
Microscopic polyangiitis, n | 4 | |||
Other vasculitis syndrome, n | 2 | |||
ANCA-positive, n (%)† | 19 (67) | |||
BVAS | 0 (0–4) | 0 (0–0) | 4.5 (4–5) | 0.0003 |
Demographic | ||||
Females/males, n | 10/18 | 7/13 | 3/5 | 0.57†† |
Age, yrs | 50 (20–54) | 53 (50–59) | 47 (20–50) | 0.30 |
Body weight, kg | 72.5 (65–85) | 72.5 (66–82) | 74 (60–82) | 0.62 |
Biological | ||||
GFR, ml/min/1.73 m2 | 80 (74–133) | 79 (74–83) | 81 (72–85) | 0.64 |
Albumin, g/l | 43.5 (38.4–44.5) | 41.3 (38–44) | 47.6 (45–49) | 0.28 |
Treatment | ||||
MMF, g/day | 2 (2–2) | 2 (2–2) | 2 (2–2) | 0.7 |
Months of MMF therapy, n | 10 (6–12) | 12 (6–12) | 9 (6–12) | 0.5 |
Corticosteroids, mg/day | 10 (5–20) | 10 (5–12) | 32 (11–45) | 0.09 |
MPA pharmacokinetics | ||||
AUC0–12h, mg•h/l | 56 (37.4–80.8) | 65.7 (40.5–81.3) | 34.8 (28.2–55) | 0.09 |
C12h, mg/l | 2.8 (1.3–4.3) | 2.9 (1.7–4.9) | 1.3 (0.9–1.7) | 0.02 |
Correlations# | ||||
AUC0–12h and C12h | r = 0.78, p = 0.0001# | |||
AUC0–12h and prednisone dose | r = −0.18, p = 0.46# |
Values are expressed as medians (interquartile range) unless otherwise stated.
↵* Mann-Whitney U test.
↵** Granulomatosis with polyangiitis.
↵*** Eosinophilic granulomatosis with polyangiitis.
↵† By indirect immunofluorescence or enzyme-linked immunosorbent assay.
↵†† Fisher exact test.
↵# Spearman correlation test. AUC: area under the curve; BVAS: Birmingham Vasculitis Activity Score; GFR; glomerular filtration rate, Cockcroft-Gault formula; MMF: mycophenolate mofetil; MPA: mycophenolic acid; ANCA: antineutrophil cytoplasmic antibody.